Tezosentan Explained

Tezosentan is a non-selective ETA and ETB receptor antagonist.[1] It acts as a vasodilator and was designed by Actelion as a therapy for patients with acute heart failure. However, studies showed that tezosentan did not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.[2]

Notes and References

  1. Urbanowicz W, Sogni P, Moreau R, Tazi KA, Barriere E, Poirel O, Martin A, Guimont MC, Cazals-Hatem D, Lebrec D . 6 . Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats . Gut . 53 . 12 . 1844–9 . December 2004 . 15542526 . 1774327 . 10.1136/gut.2003.036517 . BMJ Publishing Group Ltd & British Society of Gastroenterology .
  2. Web site: Tezosentan does not appear to improve symptoms for patients with acute heart failure . 2007-11-24 . 7 Nov 2007 . Medical Studies/Trials . news-medical.net.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Tezosentan".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.